Kuala lumpur: The success of Phase 3 of the Randomised Clinical Trial (RCT) of Nuvastatic, a product developed by local company NatureCeuticals Sdn Bhd, proves Malaysia's capability to develop high-value therapeutic innovations based on local biodiversity through international scientific standards, including randomised controlled clinical trials.

According to BERNAMA News Agency, the Agriculture and Food Security Ministry (KPKM) highlighted that Nuvastatic is a clinically validated botanical medicine specifically developed for the management of cancer-related fatigue among advanced-stage breast cancer patients undergoing treatment. This achievement is considered a historic moment for Malaysia, representing one of the country's most significant successes in pharmaceutical and oncology research development.

The ministry stated that the entire development programme, from initial discovery, preclinical studies, formulation development, Good Manufacturing Practice (GMP) manufacturing preparation, to clinical trials, was realised through continuous government support. This support was particularly under the Agriculture Flagship Project Initiative: High-Value Herbal Products overseen by the ministry from 2011 until the project's completion this year.

Nuvastatic has now been adopted by local oncologists as well as international cancer care provider networks, including those in Malaysia. The ministry extended its congratulations to NatureCeuticals Sdn Bhd, the Institute for Medical Research (IMR), clinical researchers, oncologists, research partners, patients, and all stakeholders who contributed throughout the scientific and clinical development process.